Università Campus Bio-Medico di Roma e Campus Bio-Medico University Hospital Foundation have signed a framework agreement with IRBM extension, important scientific and pharmaceutical research center specialized in "drug discovery": discovery of new drugs, biochemistry and molecular biology in sectors such as oncology, neurodegenerative diseases and infectious diseases. The agreement will develop in the areas of research and development in pharmacology, oncology, neuroscience, musculoskeletal system, infectious diseases and biopharmaceutics.

The framework agreement provides, in particular, the possibility of creating teaching and research projects; to programs research for the development of new therapies and new technologies also through access to the respective laboratories; programs of research for the advancement of scientific knowledge; participation of university teaching-researchers and IRBM staff in studies and research; the exchange of students, doctoral students, graduates, researchers o teachers; the joint organization of scientific seminars, conferences or symposiums and initiatives of common interest; collaboration in initiatives to disseminate scientific culture.

"This important agreement - has explained Carlo Tosti, the President of UCBM and FPUCBM - has the ambition of triangulating research collaborations aimed at the development of innovative drugs. The model which inspires the agreement is that of a collaboration hub between pharmaceutical research, universities and research and treatment centers in which, each with their own skills, can contribute to the identification of new disease targets and their validation. therapeutics until the development of new drugs. The areas in which the collaborations will focus will mainly concern the therapeutic areas of oncology, with particular interest in rare tumors including those of the osteo-articular system, and the therapeutic areas of neurodegenerative proteinopathies including Alzheimer's disease, Parkinson's disease and sclerosis Lateral Amyotrophic".

"We are excited to begin this collaboration - Ofchiara the President and CEO of IRBM Ilaria Di Lorenzo – This agreement establishes the joint commitment in combining the skills and resources of academia, industry and clinics for the strengthening of translational research with the common objective of accelerating the discovery and development of new therapeutic solutions and innovative drugs. The synergy between academic experience UCBM and the clinical practice of FPUCBM, combined with IRBM's industrial expertise in Drug Discovery, therefore opens new perspectives in the treatment of complex pathologies and in the development of new technologies in the field of oncology, neurodegenerative diseases and beyond".

The President and CEO of IRBM were present at the signing Ilaria Di Lorenzo and the CEO Matteo Liguori; the Rector UCBM Eugenio Guglielmelli and the CEO and General Manager UCBM Andrea Rossi; for the Campus Bio-Medico University Polyclinic Foundation the President Carlo Tosti and the CEO and General Manager Paolo Sormani. The signing took place in the presence of the top management and scientific and research managers of the three institutions.